MYGN - Myriad Genetics, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Salt Lake City,
United States
Type: Equity
MYGN price evolution
MYGN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $92.4 | $96.9 | $132.1 | |
| Short term investments | $4.9 | $7.4 | $8.8 | |
| Net receivables | $117.8 | $118.1 | $114.3 | |
| Inventory | $26.1 | $24.6 | $22 | |
| Total current assets | $291.6 | $290.3 | $313.6 | |
| Long term investments | ||||
| Property, plant & equipment | $172.8 | $177.4 | $180.6 | |
| Goodwill & intangible assets | $605.8 | $627.9 | $636.9 | |
| Total noncurrent assets | $793.5 | $820.2 | $832.9 | |
| Total investments | $4.9 | $7.4 | $8.8 | |
| Total assets | $1085.1 | $1110.5 | $1146.5 | |
| Current liabilities | ||||
| Accounts payable | $33.3 | $33.1 | $25.8 | |
| Deferred revenue | ||||
| Short long term debt | $13.3 | $13.8 | $16.2 | |
| Total current liabilities | $148.9 | $146.1 | $155.9 | |
| Long term debt | $130 | $133 | $135.9 | |
| Total noncurrent liabilities | $195.7 | $204.4 | $207.4 | |
| Total debt | $143.3 | $146.8 | $152.1 | |
| Total liabilities | $344.6 | $350.5 | $363.3 | |
| Shareholders' equity | ||||
| Retained earnings | -$692.2 | -$655.5 | -$629.5 | |
| Other shareholder equity | -$4 | -$4.2 | -$3.7 | |
| Total shareholder equity | $740.5 | $760 | $783.2 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $132.1 | $53.6 | $258.4 | $163.7 |
| Short term investments | $8.8 | $58 | $81.4 | $54.1 |
| Net receivables | $114.3 | $101.6 | $91.3 | $71 |
| Inventory | $22 | $20.1 | $15.3 | $29.1 |
| Total current assets | $313.6 | $274.6 | $484.8 | $331.7 |
| Long term investments | $54.8 | $59 | $37 | |
| Property, plant & equipment | $180.6 | $187.3 | $125.3 | $103 |
| Goodwill & intangible assets | $636.9 | $666.5 | $643.3 | $932.9 |
| Total noncurrent assets | $832.9 | $924.1 | $835.9 | $1072.9 |
| Total investments | $8.8 | $112.8 | $140.4 | $91.1 |
| Total assets | $1146.5 | $1198.7 | $1320.7 | $1404.6 |
| Current liabilities | ||||
| Accounts payable | $25.8 | $28.8 | $29.6 | $21.7 |
| Deferred revenue | $5.2 | $32.8 | ||
| Short long term debt | $16.2 | $14.1 | $13 | $13.5 |
| Total current liabilities | $155.9 | $137.2 | $204.3 | $147 |
| Long term debt | $135.9 | $130.9 | $79.3 | $281.3 |
| Total noncurrent liabilities | $207.4 | $175.7 | $148.6 | $339.4 |
| Total debt | $152.1 | $145 | $92.3 | $294.8 |
| Total liabilities | $363.3 | $312.9 | $352.9 | $486.4 |
| Shareholders' equity | ||||
| Retained earnings | -$629.5 | -$366.2 | -$254.2 | -$173.9 |
| Other shareholder equity | -$3.7 | -$8.9 | -$5.1 | -$5.2 |
| Total shareholder equity | $783.2 | $885.8 | $967.8 | $918.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $213.3 | $211.5 | $202.2 | $196.6 |
| Cost of revenue | $64.4 | $64.6 | $61.6 | |
| Gross Profit | $149.8 | $147.1 | $137.6 | $135 |
| Operating activities | ||||
| Research & development | $27.1 | $24.9 | $21 | |
| Selling, general & administrative | $144.9 | $140.6 | $144.4 | |
| Total operating expenses | $167.6 | $183.6 | $165.5 | $166.4 |
| Operating income | -$36.5 | -$27.9 | -$31.4 | |
| Income from continuing operations | ||||
| EBIT | -$36.4 | -$25.4 | -$31.4 | |
| Income tax expense | $0.9 | -$0.5 | $0.1 | -$1.1 |
| Interest expense | -$0.4 | $0.8 | $0.5 | $0.9 |
| Net income | ||||
| Net income | -$22.1 | -$36.7 | -$26 | -$31.2 |
| Income (for common shares) | -$36.7 | -$26 | -$31.2 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $753.2 | $678.4 | $690.6 | $638.6 |
| Cost of revenue | $236.2 | $202 | $197.6 | $186.1 |
| Gross Profit | $517 | $476.4 | $493 | $452.5 |
| Operating activities | ||||
| Research & development | $88.7 | $85.4 | $81.9 | $77.2 |
| Selling, general & administrative | $572.9 | $514.7 | $537.8 | $510.1 |
| Total operating expenses | $774.4 | $617 | $683.5 | $687 |
| Operating income | -$257.4 | -$140.6 | -$190.5 | -$234.5 |
| Income from continuing operations | ||||
| EBIT | -$259.3 | -$137.4 | -$50.5 | -$212.4 |
| Income tax expense | $1.1 | -$28.6 | -$29.9 | -$23.7 |
| Interest expense | $2.9 | $3.2 | $6.6 | $10.8 |
| Net income | ||||
| Net income | -$263.3 | -$112 | -$27.2 | -$199.5 |
| Income (for common shares) | -$263.3 | -$112 | -$27.2 | -$199.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$36.7 | -$26 | -$31.2 | |
| Operating activities | ||||
| Depreciation | $17.2 | $18 | $17.8 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.5 | $12 | $10.4 | |
| Total cash flows from operations | $2.6 | -$18.6 | -$54.7 | |
| Investing activities | ||||
| Capital expenditures | -$8.9 | -$8.6 | -$13.5 | |
| Investments | $2.5 | $1.5 | $1.5 | |
| Total cash flows from investing | -$6 | -$6.4 | -$7.1 | -$12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3 | $123.6 | ||
| Net borrowings | -$0.1 | -$0.1 | -$0.2 | |
| Total cash flows from financing | -$9.5 | $2.4 | -$8.8 | $121.9 |
| Effect of exchange rate | -$0.3 | -$0.7 | -$0.8 | $0.7 |
| Change in cash and equivalents | -$31.1 | -$4.4 | -$35.3 | $55.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$263.3 | -$112 | -$27.2 | -$199.5 |
| Operating activities | ||||
| Depreciation | $73.2 | $64.4 | $75.6 | $72 |
| Business acquisitions & disposals | -$57.2 | $379.1 | $21.3 | |
| Stock-based compensation | $40.7 | $38.1 | $36.3 | $25.2 |
| Total cash flows from operations | -$110.9 | -$106.3 | $18.2 | $60.7 |
| Investing activities | ||||
| Capital expenditures | -$73.3 | -$45.3 | -$18 | -$10.2 |
| Investments | $105.2 | $25 | -$86.7 | $8.2 |
| Total cash flows from investing | $31.9 | -$77.5 | $274.4 | $19.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $123.6 | $6.3 | $91.8 | $3.5 |
| Net borrowings | $38.1 | -$0.7 | -$227.6 | -$9.6 |
| Total cash flows from financing | $152.9 | -$8 | -$150.6 | -$10 |
| Effect of exchange rate | $0.6 | -$0.6 | -$0.6 | $0.5 |
| Change in cash and equivalents | $74.5 | -$192.4 | $141.4 | $70.5 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $823.60M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$116.00M |
| Revenue Q/Q | 11.15% |
| Revenue Y/Y | 12.15% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.46 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |